

MY FUTURE VISION FOR THE IJCEO



I am delighted to present this inaugural issue of **Indian Journal of Clinical and Experimental Ophthalmology “(IJCEO)”**. It gives me great pleasure to write as the Editor in Chief of IJCEO. I can understand that editing a medical journal is an important and challenging responsibility. Our first priority is to provide quality research and scientific articles in each issue of our journal to readers on time. We are proud to announce that the journal will be available online and the articles can thus be easily accessible free of charge to readers worldwide. As an onward progress, the special issue for different subspecialty of Ophthalmology will be published in the journal, by experts of national and international repute, which will certainly benefit the young Ophthalmologists and allied health care providers in developing countries.

India still has high prevalence of blindness as a result of various morbidities like infections, Glaucoma, trauma, tumors and systemic diseases like hypertension and Diabetes. In 2012 WHO estimated that more than 200 million people will be suffering

from diabetes and by 2030 this number will double. Most of the Diabetic population reside in India and China. Diabetes mellitus is a major cause of avoidable blindness, overall prevalence of Diabetic retinopathy is increasing from reported value (17.6%)¹. Macular edema or retinal thickening is an important manifestation of Diabetic Retinopathy and one of the common cause of visual loss. Recently intravitreal Anti VEGF has significant roll in treatment of DME². The goal of this issue is to update ophthalmologists on topics they may have learned during training and also to introduce a number of new diagnostic and therapeutic options in Diabetic macular disorders. A study predictor of visual response to intravitreal Bevacizumab for treatment of DME which has been published in this issue of IJCEO has shown that macular ischemia and intact IS /OS are important predictors for visual response to intravitreal Bevacizumab.

We hope that the collection of studies will improve both the knowledge and level of care offered by ophthalmologists to their patients. The success of IJCEO will not only

depend on the editors and reviewers but also on the participation of readers and contributors. I would like to request all fellow Ophthalmologists to join us in publishing their scientific research articles and make

our journey successful and useful to us and our patients. I would like to encourage fellow ophthalmologists to access Indian Journal of Clinical and Experimental Ophthalmology.

References:

1. Rema M, Ponnaiya M, Mohan V. Prevalence of retinopathy in non-insulin dependent diabetes mellitus at a diabetes center in Southern India. *Diabetes RES Clin Pract* 1996;34:29-36.
2. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology* 2007; 114: 1860-1867 [PMID: 17698196 DOI: 10.1016/j.ophtha.2007.05.062]

Rajendra P Maurya

Editor in Chief IJCEO

Assistant Professor

Department of Ophthalmology,

Institute of Medical Sciences,

Banaras Hindu University, Varanasi, (UP), INDIA

E-mail: editorijceo@gmail.com, mauryarp_bhu@yahoo.com